Raghu, Ganesh

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisConnective Tissue Growth Factor Research

Cited by 293

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

Raghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., et al. (2017) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 278

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 277

An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial

Khanna, D., Albera, C., Fischer, A., Khalidi, N., Raghu, G., Chung, L., Chen, D., Schiopu, E., Tagliaferri, M., Seibold, J. R., et al. (2016) · The Journal of Rheumatology

Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 268

Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials

Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., Martinez, F. J., & Brown, K. K. (2012) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisStatistical Methods in Clinical Trials

Cited by 242

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 196

Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria

Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 180

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 148

Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years

Raghu, G. (2017) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 146

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis

Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 101

Current approaches to the management of idiopathic pulmonary fibrosis

Raghu, G., & Richeldi, L. (2017) · Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 90

Telemedicine — maintaining quality during times of transition

Romanick-Schmiedl, S., & Raghu, G. (2020) · Nature Reviews Disease Primers

Telemedicine and Telehealth ImplementationHealthcare Systems and Technology

Cited by 75

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial

West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., et al. (2023) · Thorax

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 67